Development and validation of a cardiovascular risk assessment model in patients with established coronary artery disease

American Journal of Cardiology

Volumn 112, Issue 1, 2013, Pages 27-33

  Battes, Linda ^a   Barendse, Rogier ^a   Steyerberg, Ewout W ^a   Simoons, Maarten L ^a   Deckers, Jaap W ^a   Nieboer, Daan ^a   Bertrand, Michel ^b   Ferrari, Roberto ^c   Remme, Willem J ^d   Fox, Kim ^e   Takkenberg, Johanna J M ^a   Boersma, Eric ^a   Kardys, Isabella ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Lille Heart Institute   (France)

^c UNIVERSITY OF FERRARA   (Italy)

^d Sticares Cardiovascular Research Foundation   (Netherlands)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; PERINDOPRIL; PLACEBO;

ADULT; BODY MASS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART ARREST; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; REVASCULARIZATION; SMOKING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AREA UNDER CURVE; CALIBRATION; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PERINDOPRIL; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84879115850     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.02.049     Document Type: Conference Paper

References (26)

1. R.M. Conroy, K. Pyorala, A.P. Fitzgerald, S. Sans, A. Menotti, G. De Backer, D. De Bacquer, P. Ducimetiere, P. Jousilahti, U. Keil, I. Njolstad, R.G. Oganov, T. Thomsen, H. Tunstall-Pedoe, A. Tverdal, H. Wedel, P. Whincup, L. Wilhelmsen, and I.M. Graham Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J 24 2003 987 1003
2. R. Voss, P. Cullen, H. Schulte, and G. Assmann Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Münster Study (PROCAM) using neural networks Int J Epidemiol 31 2002 1253 1262 discussion 1262-1264
3. W.B. Kannel, D. McGee, and T. Gordon A general cardiovascular risk profile: the Framingham study Am J Cardiol 38 1976 46 51
4. J. Hippisley-Cox, C. Coupland, Y. Vinogradova, J. Robson, M. May, and P. Brindle Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study BMJ 335 2007 136
5. T.C. Clayton, J. Lubsen, S.J. Pocock, Z. Voko, B.A. Kirwan, K.A. Fox, and P.A. Poole-Wilson Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients BMJ 331 2005 869
6. C. Prugger, J. Wellmann, J. Heidrich, S.M. Brand-Herrmann, and U. Keil Cardiovascular risk factors and mortality in patients with coronary heart disease Eur J Epidemiol 23 2008 731 737
7. F. Haverkate, S.G. Thompson, S.D. Pyke, J.R. Gallimore, and M.B. Pepys Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group Lancet 349 1997 462 466
8. I.C. Marschner, D. Colquhoun, R.J. Simes, P. Glasziou, P. Harris, B.B. Singh, D. Friedlander, H. White, P. Thompson, and A. Tonkin Long-term risk stratification for survivors of acute coronary syndromes: results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators J Am Coll Cardiol 38 2001 56 63
9. B. Unal, S. Capewell, and J.A. Critchley Coronary heart disease policy models: a systematic review BMC Public Health 6 2006 213
10. R. Marchioli, F. Avanzini, F. Barzi, C. Chieffo, A. Di Castelnuovo, M.G. Franzosi, E. Geraci, A.P. Maggioni, R.M. Marfisi, N. Mininni, G.L. Nicolosi, M. Santini, C. Schweiger, L. Tavazzi, G. Tognoni, and F. Valagussa Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart Eur Heart J 22 2001 2085 2103
11. K.M. Fox, and EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 362 2003 782 788
12. E.W. Steyerberg Clinical Prediction Models: A Practical Approach to Development, Validation and Updating 2008 Springer New York
13. M. Visser [Roaming through methodology. XXXIV. Limitations of predictive models] Ned Tijdschr Geneeskd 145 2001 1109 1112
14. J.W. Deckers, D.M. Goedhart, E. Boersma, A. Briggs, M. Bertrand, R. Ferrari, W.J. Remme, K. Fox, and M.L. Simoons Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk Eur Heart J 27 2006 796 801
15. A.P. Dempster, N.M. Laird, and D.B. Rubin Maximum likelihood from incomplete data via the EM algorithm J Royal Stat Soc Series B (Stat Method) 39 1977 1 38
16. L.E. Chambless, C.P. Cummiskey, and G. Cui Several methods to assess improvement in risk prediction models: extension to survival analysis Stat Med 30 2011 22 38
17. Available at: http://cran.r-project.org/web/packages/survivalROC/ survivalROC.pdf. Accessed on December 20, 2012.
18. M.H. Zweig, and G. Campbell Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine Clin Chem 39 1993 561 577
19. M. Gonen Analyzing Receiver Operating Characteristic Curves with SAS 2007 SAS Institute Cary, North Carolina
20. M. St. John Sutton, M.A. Pfeffer, L. Moye, T. Plappert, J.L. Rouleau, G. Lamas, J. Rouleau, J.O. Parker, M.O. Arnold, B. Sussex, and E. Braunwald Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial Circulation 96 1997 3294 3299
21. A.C. Maas, R.T. van Domburg, J.W. Deckers, F. Vermeer, W.J. Remme, O. Kamp, V. Manger Cats, and M.L. Simoons Sustained benefit at 10-14 years follow-up after thrombolytic therapy in myocardial infarction Eur Heart J 20 1999 819 826
22. A.M. Walker Confounding by indication Epidemiology 7 1996 335 336
23. S. Blankenberg, M.J. McQueen, M. Smieja, J. Pogue, C. Balion, E. Lonn, H.J. Rupprecht, C. Bickel, L. Tiret, F. Cambien, H. Gerstein, T. Munzel, and S. Yusuf Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) study Circulation 114 2006 201 208
24. M. Singh, D.R. Holmes, R.J. Lennon, and C.S. Rihal Development and validation of risk adjustment models for long-term mortality and myocardial infarction following percutaneous coronary interventions Circ Cardiovasc Interv 3 2010 423 430
25. C. Lenfant Shattuck lecture - clinical research to clinical practice - lost in translation? N Engl J Med 349 2003 868 874
26. A. Ash, and M. Shwartz R2: a useful measure of model performance when predicting a dichotomous outcome Stat Med 18 1999 375 384